EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies

Mark Dransfield, Nathaniel Marchetti, Ravi Kalhan, Daniel Reyner, Amy L Dixon, Tara Rheault, Kathleen Ann Rickard, Antonio Anzueto iD

Chronic Respiratory Disease · 2025-12 · 22

DOI: 10.1177/14799731251314874 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Chronic Respiratory Disease, online erschienen am 24.01.2025. Verfasst von Mark Dransfield und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medicine/Pulmonary, Allergy and Critical Care, University of Alabama at Birmingham and the Birmingham VA Medical Center, Birmingham, AL, USA. Hauptthemen laut MEDLINE: Bronchodilator Agents, Muscarinic Antagonists, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Verona Pharma plc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy and safety of ensifentrine, a novel PDE3/PDE4 inhibitor, were previously evaluated in the ENHANCE-1 (NCT04535986) and ENHANCE-2 (NCT04542057) trials. Here, we present a pooled post-hoc subgroup analysis of patients according to background chronic obstructive pulmonary disease (COPD) maintenance medication regimens.

Objective

This analysis aimed to explore the efficacy and safety of ensifentrine in patients receiving long-acting muscarinic antagonists (LAMA) or long-acting beta-agonists with inhaled corticosteroids (LABA + ICS).

Methods

Eligible patients had moderate to severe COPD, were aged 40–80 years, and were symptomatic at randomization. Patients were randomized 5:3, receiving twice-daily ensifentrine 3 mg or placebo via standard jet nebulizer over 24 weeks.

Results

The pooled post-hoc analysis included 485 LAMA patients and 272 LABA + ICS patients. Ensifentrine showed lung function improvement over placebo at week 12, including average FEV 1 AUC 0–12 h in the LAMA (placebo-corrected least squares mean change from baseline [LSMC], 92 mL; 95% CI, 54, 131; p < 0.001) and LABA + ICS subgroups (LSMC, 74 mL; 95% CI, 27, 121; p = 0.002). Ensifentrine reduced the rate and risk of exacerbations in both LAMA (48% and 50%, respectively) and LABA + ICS (51% and 56%, respectively) subgroups. Ensifentrine-treated patients reported improvement in symptoms and quality of life over 24 weeks. The safety profile of ensifentrine in each subgroup was similar to the profile in the pooled modified intention-to-treat population.

Conclusions

Nebulized ensifentrine offers a novel non-steroidal anti-inflammatory and bronchodilator treatment added to existing LAMA or LABA + ICS treatment options in patients with moderate to severe, symptomatic COPD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchodilator AgentsMuscarinic AntagonistsPulmonary Disease, Chronic ObstructiveAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdministration, InhalationAdrenal Cortex HormonesAdrenergic beta-AgonistsDrug Therapy, CombinationForced Expiratory VolumeQuality of LifeTreatment OutcomeIsoquinolinesPyrimidinones

Stichwörter der Autor:innen

Chronic obstructive pulmonary diseasedual PDE3 and PDE4 inhibitorensifentrinemaintenance therapy

Substanzen

Adrenal Cortex HormonesAdrenergic beta-AgonistsBronchodilator AgentsensifentrineMuscarinic AntagonistsIsoquinolinesPyrimidinones

Autor:innen und Institutionen

  • Medicine/Pulmonary, Allergy and Critical Care, University of Alabama at Birmingham and the Birmingham VA Medical Center, Birmingham, AL, USA.
  • Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
  • Division of Pulmonary and Critical Care Medicine, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Verona Pharma plc, Raleigh, NC, USA.
  • South Texas Veterans Health Care System, University of Texas Health, San Antonio, TX, USA.

ORCID-Profile: Antonio Anzueto

Förderung

  • Verona Pharma plc

Zitieren

APA

Dransfield, M., Marchetti, N., Kalhan, R., Reyner, D., Dixon, A. L., Rheault, T., Rickard, K. A., & Anzueto, A. (2025). Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies. Chronic Respiratory Disease, 22. https://doi.org/10.1177/14799731251314874

Vancouver

Dransfield M, Marchetti N, Kalhan R, Reyner D, Dixon AL, Rheault T, et al. Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies. Chronic Respiratory Disease. 2025;22. doi:10.1177/14799731251314874

BibTeX
@article{Dransfield2025,
  author = {Dransfield, Mark and Marchetti, Nathaniel and Kalhan, Ravi and Reyner, Daniel and Dixon, Amy L and Rheault, Tara and Rickard, Kathleen Ann and Anzueto, Antonio},
  title = {Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies},
  journal = {Chronic Respiratory Disease},
  year = {2025},
  volume = {22},
  doi = {10.1177/14799731251314874}
}
Kostenlos starten →